Literature DB >> 21748054

Familial mineralocorticoid induced hypertension in the sultanate of oman.

Nicholas Jy Woodhouse1, Omayma T Elshafie, Fatma Ben Abid, Suhail A Doi.   

Abstract

OBJECTIVES: In Oman, many hypertensive patients with a family history of the disease respond to treatment with spironolactone, a mineralocorticoid receptor (MC-R) blocking agent thus suggesting a high prevalence of mineralocorticoid (MC) induced disease. The aim of this study was to document the prevalence of MC induced disease in patients with a positive family history of hypertension (HTN).
METHODS: Serum calcium, potassium, creatinine, aldosterone and renin levels were measured under standard conditions in all patients together with an abdominal ultrasound scan and an adrenal computed tomography (CT) scan in four patients.
RESULTS: In this small study, we show that 18 of the 27 patients (66%) had undetectable (suppressed) renin levels with usually normal aldosterone values (14 patients) and respond to treatment with spironoactone.
CONCLUSION: We suggest that MC induced hypertension is likely to be common in the Middle East. In evolutionary terms, this makes sense as the ability to conserve salt in hot climates might be expected to confer a definite survival advantage.

Entities:  

Keywords:  High prevalence; Hypertension, familial; Mineralocorticoids; Oman

Year:  2008        PMID: 21748054      PMCID: PMC3074815     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  12 in total

1.  Dexamethasone-suppressible hypertension.

Authors:  P M Stewart
Journal:  Lancet       Date:  2000-08-26       Impact factor: 79.321

2.  Spironolactone responsive familial hypertension. A potentially high prevalence of mineralocorticoid disease in Oman.

Authors:  Nicholas J Woodhouse; Omiema T Elshafie; Ali Mehar; W J Johnston; Juma M Al-Kaabi
Journal:  Saudi Med J       Date:  2003-02       Impact factor: 1.484

3.  Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity.

Authors:  Albertina So; David L Duffy; Richard D Gordon; Yvette W A Jeske; Karen Lin-Su; Maria I New; Michael Stowasser
Journal:  J Hypertens       Date:  2005-08       Impact factor: 4.844

Review 4.  Primary aldosteronism.

Authors:  A Ganguly
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

Review 5.  Familial varieties of primary aldosteronism.

Authors:  M Stowasser; T G Gunasekera; R D Gordon
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-12       Impact factor: 2.557

6.  Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers.

Authors:  R D Gordon; M D Ziesak; T J Tunny; M Stowasser; S A Klemm
Journal:  Clin Exp Pharmacol Physiol       Date:  1993-05       Impact factor: 2.557

7.  Clinical and pathological diversity of primary aldosteronism, including a new familial variety.

Authors:  R D Gordon; M Stowasser; T J Tunny; S A Klemm; W L Finn; A L Krek
Journal:  Clin Exp Pharmacol Physiol       Date:  1991-05       Impact factor: 2.557

Review 8.  Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today?

Authors:  Clarence E Grim
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

9.  Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing.

Authors:  Sue Hood; John Cannon; Roger Foo; Morris Brown
Journal:  Clin Med (Lond)       Date:  2005 Jan-Feb       Impact factor: 2.659

10.  Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.

Authors:  C Seifarth; S Trenkel; H Schobel; E G Hahn; J Hensen
Journal:  Clin Endocrinol (Oxf)       Date:  2002-10       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.